Oncolytics Biotech

ONCYPhase 3

Calgary, CanadaFounded 1998oncolyticsbiotech.com

Oncolytics Biotech is advancing pelareorep, a unique oncolytic virus that selectively replicates in cancer cells and stimulates a systemic anti-tumor immune response. The company's strategy is centered on GI cancers, where it has generated compelling clinical data, including a 62% objective response rate in first-line mPDAC and more than doubled survival benchmarks in KRAS-mutant mCRC. With a seasoned leadership team and a clear focus on registration-enabling studies, Oncolytics aims to bring a novel, tolerable immunotherapy to patients facing devastating GI malignancies.

Market Cap

$102.2M

Founded

1998

Focus

BiologicsDrug DeliveryViral Technology

ONCY · Stock Price

USD 0.950.68 (-41.72%)

Historical price data

AI Company Overview

Technology Platform

Pelareorep is a first-in-class, intravenously delivered, double-stranded RNA (dsRNA) oncolytic virus that selectively replicates in cancer cells to stimulate a systemic anti-tumor immune response and remodel the tumor microenvironment.

Pipeline Snapshot

20 drugs in pipeline, 1 in Phase 3

Drug	Indication	Stage
REOLYSIN + Carboplatin + Paclitaxel + Placebo	Carcinoma, Squamous Cell of the Head and Neck	Phase 3
Pemetrexed and Reolysin (and safety run-in) + Pemetrexed + Docetaxel and Reolysi...	Non Small Cell Lung Cancer	Phase 2
Docetaxel, Reolysin and Prednisone + Docetaxel and Prednisone	Prostate Cancer	Phase 2
REOLYSIN® + Carboplatin + Paclitaxel	Carcinoma, Squamous Cell of the Head and Neck	Phase 2
REOLYSIN®	Osteosarcoma	Phase 2

Opportunities

Oncolytics' primary growth opportunity lies in successfully developing pelareorep as a platform immunotherapy across multiple GI cancers, starting with mPDAC and KRAS-mutant mCRC.

Success in these multi-billion dollar markets could lead to expansion into other RAS-pathway activated tumors.

The favorable safety profile also creates opportunities for combination with a wide array of other oncology therapeutics.

Risk Factors

Key risks include the failure of pelareorep in larger, randomized clinical trials, the company's dependence on raising additional capital to fund expensive late-stage studies, intense competition in oncology, and the inherent regulatory uncertainties of drug development.

The company's value is concentrated in a single asset.

Competitive Landscape

Oncolytics competes in a landscape dominated by chemotherapy for GI cancers. Its main differentiation is pelareorep's ability to make 'cold' tumors responsive to immunotherapy, a major unmet need. Competitors include other oncolytic virus developers and targeted therapy companies, but pelareorep's systemic delivery and focus on GI cancers provide a distinct niche.